Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel versus weekly paclitaxel in first-line HER2-negative metastatic breast cancer
2014-000918-61Phase 2Unknown
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- May 2014
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in breast cancer comparing Cabazitaxel 3-weekly with Paclitaxel weekly (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
cabazitaxelpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-000918-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000918-61.